| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ANTIMICROBIAL AGENTS |
Department of Molecular Microbiology and Immunology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
Corresponding author: Dr Y. Zhang (e-mail: yzhang{at}jhsph.edu).
Received 14 May 2001; revised version accepted 4 July 2001.
Abstract
Pyrazinamide (PZA) is an important front-line anti-tuberculosis drug that is active only at acid pH. However, acid pH causes significant difficulty for PZA susceptibility testing. A common problem in PZA testing is false resistance caused by large bacterial inocula. This study investigated the relationship of false resistance to numbers of bacilli, pH and other factors that potentially affect susceptibility to PZA. Large inocula (107--8 bacilli/ml) of M. tuberculosis H37Ra caused significant increase in medium pH from 5.5 towards neutrality, and thus produced false resistance results. The increase in medium pH was determined to be a function of live bacilli; heat-killed bacilli had little or no effect. Susceptibility to PZA and its active derivative pyrazinoic acid (POA) was comparable on 7H11 agar medium, but POA was less active than PZA in liquid medium containing bovine serum albumin (BSA), suggesting that susceptibility to PZA or POA was reduced in the presence of BSA, because of its neutralising effect on medium pH and significant POA binding. A 3-month-old H37Ra culture was shown to be more susceptible to PZA exposure than a 4-day log-phase culture, suggesting that PZA is more active for non-growing bacilli. Finally, reserpine, an inhibitor of POA efflux pump, increased susceptibility to PZA even near neutral pH 6.8, with an MIC of 400 mg/L compared with 1000 mg/L without reserpine. These findings should have implications for understanding the mode of action of PZA and for PZA susceptibility testing.
This article has been cited by other articles:
|
|
 |
|
  R. J. Rieder, Z. Zhao, and B. Zavizion New Approach for Drug Susceptibility Testing: Monitoring the Stress Response of Mycobacteria Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4598 - 4603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sheen, M. Mendez, R. H. Gilman, L. Pena, L. Caviedes, M. J. Zimic, Y. Zhang, D. A. J. Moore, and C. A. Evans Sputum PCR-Single-Strand Conformational Polymorphism Test for Same-Day Detection of Pyrazinamide Resistance in Tuberculosis Patients J. Clin. Microbiol., September 1, 2009; 47(9): 2937 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Gumbo, C. S. W. Siyambalapitiyage Dona, C. Meek, and R. Leff Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3197 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Louw, R. M. Warren, N. C. Gey van Pittius, C. R. E. McEvoy, P. D. Van Helden, and T. C. Victor A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance Antimicrob. Agents Chemother., August 1, 2009; 53(8): 3181 - 3189. [Full Text] [PDF]
|
|
|
|
|
|
P. Jureen, J. Werngren, J.-C. Toro, and S. Hoffner Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1852 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Byrne, S. M. Denkin, P. Gu, E. Nuermberger, and Y. Zhang Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model J. Med. Microbiol., August 1, 2007; 56(8): 1047 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Ngo, O. Zimhony, W. J. Chung, H. Sayahi, W. R. Jacobs Jr., and J. T. Welch Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2430 - 2435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Zimhony, C. Vilcheze, M. Arai, J. T. Welch, and W. R. Jacobs Jr. Pyrazinoic Acid and Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating Tubercle Bacilli Antimicrob. Agents Chemother., February 1, 2007; 51(2): 752 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Wade and Y. Zhang Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro J. Antimicrob. Chemother., November 1, 2006; 58(5): 936 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Wade and Y. Zhang Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis J. Med. Microbiol., August 1, 2004; 53(8): 769 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Somoskovi, M. M. Wade, Z. Sun, and Y. Zhang Iron enhances the antituberculous activity of pyrazinamide J. Antimicrob. Chemother., February 1, 2004; 53(2): 192 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garcia-Garcia, J. Galvez, J.-V. de Julian-Ortiz, R. Garcia-Domenech, C. Munoz, R. Guna, and R. Borras New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method J. Antimicrob. Chemother., January 1, 2004; 53(1): 65 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, M. M. Wade, A. Scorpio, H. Zhang, and Z. Sun Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid J. Antimicrob. Chemother., November 1, 2003; 52(5): 790 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Madison, W. Gross, I. George, A. Sloutsky, G. Washabaugh, B. Robinson-Dunn, H. Lipman, B. Metchock, G. Mazurek, and J. Ridderhof Multicenter Evaluation of a Nonweekend Reading Schedule for Radiometric Pyrazinamide Susceptibility Testing of Mycobacterium tuberculosis J. Clin. Microbiol., October 1, 2002; 40(10): 3753 - 3756. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |
